S624
Clinical – Head & neck
ESTRO 2026
Digital Poster 3410 Locally advanced nasopharyngeal cancer in western Algeria: results and prognostic factors in a cohort of 254 cases Hakim Belmiloud 1,2 , Meriem Cheriguene 1,2 , Abdelbaki Boukerche 1,2 1 Radiotherapy, EHSO Emir Abdelkader, Oran, Algeria. 2 Medecine, University Ahmed Benbella Oran 1, Oran, Algeria Purpose/Objective: Nasopharyngeal cancer is considered a significant public health concern in Algeria. It is distinguished from other cancers of the upper aerodigestive tract by its often late onset. External beam radiotherapy remains the standard locoregional treatment for nasopharyngeal cancer, used concurrently with chemotherapy for advanced forms. Induction chemotherapy remains a recommended therapeutic approach that increases the local control rate for locally advanced cancers. The objective of this study was to evaluate the long-term therapeutic outcomes and determine the prognostic factors of locally advanced nasopharyngeal cancer in western Algeria, based on a cohort of 254 cases. Material/Methods: This retrospective study, conducted in the radiotherapy department of the Emir Abdelkader University Hospital in Oran, covered patients with locally advanced nasopharyngeal carcinoma from January 2016 to December 2019. Survival rates were estimated using the Kaplan-Meier method. The log- rank test and the Cox regression model were used for univariate and multivariate analyses, respectively. Results: Two hundred and fifty-four patients with locally advanced nasopharyngeal carcinoma were included in the study over a four-year period (2016–2019). The mean age was 46.3 ± 1.7 years (range 17–78 years), with a peak incidence at 40–49 years and a sex ratio of 1.8. The mean time to diagnosis was 8.6 ± 0.7 months. Lymph node involvement was the main reason for consultation (57.9%). Undifferentiated nasopharyngeal carcinoma (UCNT) was the most common histological type (81.9%). The majority of tumors were classified as stage IVA (53.5%) according to the 2009 UICC classification. Treatment consisted of induction chemotherapy followed by concurrent radiotherapy (68.1%) and chemotherapy followed by radiotherapy alone (31.9%). The objective post-treatment response rate was 91.7%. With a median follow-up of 90 months (range 3–118 months), the locoregional recurrence- free survival, disease-free survival, and overall survival rates at 5 and 8 years were 92.3%, 85.7%, 79.8%, 83.5%, 74.8%, and 74.3%, respectively. Induction chemotherapy followed by radiotherapy (concurrent
Digital Poster Highlight 3394 Induction chemotherapy with cisplatin-docetaxel- capecitabine (PTX), followed by concurrent chemoradiotherapy in advanced nasopharyngeal carcinomas. Hakim Belmiloud 1,2 , Meriem Cheriguene 1,2 , Abdelbaki Boukerche 1,2 1 radiotherapy, EHSO Emir Abdelkader, Oran, Algeria. 2 Medecine, university Ahmed Benbella Oran 1, Oran, Algeria Purpose/Objective: The objective of our study is to evaluate in the long term the efficacy of the Cisplatin Docetaxel- Capecitabine (PTX) induction regimen, followed by concurrent chemoradiotherapy, in terms of objective response rate, treatment tolerance, locoregional recurrence-free survival, disease-free survival and overall survival. Material/Methods: Prospective study, carried out at the radiotherapy department of the EHSO Emir Abdelkader in Oran, over a period from January 2016 to December 2019, concerning patients with locally advanced nasopharyngeal carcinoma. Results: A total of 173 patients were included in the study (108 men and 65 women), with a sex ratio of 1.6. The mean age of the patients was 43.7 ± 2.0 years. Undifferentiated carcinoma was the most frequent histological type (80.9%). The majority of tumors were classified as T4 (53.2%), N2 (70.5%), and stage IVA (46.8%), followed by stage III (42.8%) according to the 2009 UICC classification. The objective response rate after induction chemotherapy was 74.5%, with 10 progressions (5.8%). Induction chemotherapy was associated with grade 3/4 toxicity, primarily nausea (9.8%), vomiting (8%), and diarrhea (4.3%). With a median follow-up of 91 months (07–113), the respective locoregional recurrence-free survival and disease-free survival rates at 3, 5, and 8 years were 96.9%, 92.3%, and 83.5%, and 93.9%, 86.9%, and 76.3%. The mean overall survival was estimated at 97.7 months ± 4.7 months (95% confidence interval: 93.1–102.4), and the overall survival rates were 90.4%, 83.1%, and 80.1% at 3, 5, and 8 years, respectively. Conclusion: The survival results of our study are promising, with a high objective response rate and an acceptable safety profile. However, a comparison with other chemotherapy protocols would allow for a better evaluation of this new therapeutic approach, as well as for optimizing its indications within the therapeutic arsenal. Keywords: nasopharyngeal carcinoma, induction chemotherapy.
Made with FlippingBook - Share PDF online